2024. 3D MOLECULAR DOCKING COMBINED WITH AI-DRIVEN VIRTUAL SCREENING TO REPURPOSE FDA-APPROVED DRUGS FOR RARE NEURODEGENERATIVE DISEASES. International Journal of Experimental Biology. 2, 01 (Jun. 2024), 50–73.